Former Leaders of Thorne HealthTech and Tempus Launch Brain Health and Wellness Company BEVIMI at Inaugural CG Well Summit

NEW YORK, Sept. 15, 2025 — CG WELL SUMMIT — The leaders of brain health and wellness company BEVIMI today announced the launch of their company as part of the inaugural CG Well Summit. Convened by leading independent, full-service financial services firm Canaccord Genuity Group, this global summit unites thought leaders and key deal makers in the consumer health and wellness space. This morning’s opening keynote was delivered by BEVIMI Co-Founder and President Joel Dudley, Ph.D.

Kicking off the summit, Dudley’s talk, “Wellness 3.0: Charting a New Path for Personalized and Preventative Health,” addressed the transition from sick care to true health care that BEVIMI is designed to lead. Drawing from his qualifications and experience, Dudley revealed how AI, precision health, and advanced diagnostics can unlock lasting outcomes and empower people to thrive.

Later in the day, BEVIMI Co-Founder and CEO Paul Jacobson joined the summit’s expert panel “Demonstrable Consumer Outcomes: Proof Over Promises and the Brands Driving Outcomes.” As the former CEO of Thorne HealthTech, Jacobson led the company through 15 years of expansion — growing sales roughly tenfold, taking the venture public, then steering its go-private transaction. For this panel he joined leaders in women’s health, longevity, gut, and brain health who are delivering real outcomes and making science-backed solutions accessible.

BEVIMI’s Mission and Future

Serving its mission of becoming a global leader in the advancement of cognitive longevity, BEVIMI is being built on a foundation of scientific rigor, innovation, and preventative health. Together with a rapidly growing staff of proven leaders, from their headquarters in Greenwich, Connecticut, Jacobson and Dudley are developing a platform of products focused on targeting neuroinflammation and cognitive performance across multiple indications and markets.

Today the company revealed key details about its first product, currently slated for launch early next year. Designed as nutritional support for individuals at high risk of — or in preclinical stages of — Alzheimer’s disease, the product represents a breakthrough in cognitive health innovation. While a solid scientific foundation already exists for the product’s individual ingredients, it will enter an Institutional Review Board–approved, randomized, double-blind, placebo-controlled clinical study in the months ahead. The study’s primary objective is safety and tolerability; secondary and exploratory measures will assess changes across a pre-specified biomarker panel relevant to Alzheimer’s pathophysiology.

According to BEVIMI’s co-founders, cognitive decline is a multifaceted process that requires addressing several underlying mechanisms simultaneously. Their flagship product aims to be the first of its kind to deliver clinically validated, bioactive ingredients — including hard-to-deliver hydrophobic compounds — at meaningful levels in a conveniently dosed 2-ounce beverage.

“Brain health is the new heart health,” Jacobson said. “Consumers are elevating cognitive wellness to a daily priority, and the underlying science has matured. BEVIMI’s first formulation is a multi-ingredient systems approach, intentionally mapped to four well-characterized pathways in Alzheimer’s biology. Each component was selected based on convergent human safety data and preclinical evidence, with attention to bioavailability, blood–brain barrier engagement proxies, and complementary mechanisms of action. We founded BEVIMI with leading scientists to bring pharmaceutical-style rigor — target mapping, dose justification, and pre-specified endpoints — to evidence-informed nutrition.”

“Starting soon,” Dudley added, “BEVIMI will begin providing science-based nutritional support, education, and AI-driven insights to help people seeking proactive solutions for cognitive decline. Long term, our proprietary technology and focus on dampening neuroinflammation, supporting amyloid-beta (Aβ) proteostasis and clearance, reinforcing blood–brain barrier integrity, and optimizing gut-microbiome-derived metabolites that influence brain signaling will support improved outcomes across a wide spectrum of cognitive challenges, including focus, mood, sleep, and mental acuity.”

With its debut at the CG Well Summit, BEVIMI enters the wellness and brain health market with a strong scientific foundation and a clear commitment to supporting cognitive longevity for people worldwide. To stay informed about BEVIMI and its offerings — including its upcoming product launch — visit https://www.mybevimi.com.

Leadership Bios

Joel Dudley is the Co‑Founder and President of BEVIMI. He previously served as General Partner at Innovation Endeavors and as Chief Scientific Officer at Tempus, where he helped scale AI- and data-driven platforms in healthcare. Before Tempus, Dudley was an Associate Professor of Genetics & Genomic Sciences and the Founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai, and also Executive Vice President for Precision Health for the Mount Sinai Health System. He co-founded Onegevity Health (acquired by Thorne) and NuMedii, and has authored 200+ peer‑reviewed papers. He holds a B.S. in Microbiology from Arizona State University and an M.S./Ph.D. in Biomedical Informatics from Stanford University School of Medicine.

Paul Jacobson is the Co‑Founder and Chief Executive Officer of BEVIMI, bringing more than two decades of operating and capital-markets leadership. Most recently Jacobson served as CEO of Thorne HealthTech, leading the company through 15 years of expansion. Earlier, he was a private investor and served on healthcare and biotechnology boards, and was a Partner and Co‑Head of the Liquid Capital Markets group at Goldman Sachs. He holds an M.B.A. from Washington University and a B.A. in English and Economics from Vanderbilt University.

About BEVIMI

BEVIMI is a health and wellness company dedicated to advancing cognitive longevity and performance. Launched in 2025 by leading scientists to bring pharmaceutical‑style rigor to evidence‑informed nutrition, BEVIMI develops proprietary, science‑based nutritional products, support, and education. To learn more, visit https://www.mybevimi.com.

NOTE TO EDITORS: Image to accompany this story: https://darnellworks.com/bevimi/media/jd-pj-m.jpg (Caption: L‑R: BEVIMI Co‑Founder and President Joel Dudley, and Co‑Founder and Chief Executive Officer Paul Jacobson.)

SOURCE: BEVIMI